Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/123569
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Lukovic, Dunja | - |
dc.contributor.author | Stojkovic, Miodrag | - |
dc.contributor.author | Moreno-Manzano, Victoria | - |
dc.contributor.author | Bhattacharya, Shom Shanker | - |
dc.contributor.author | Erceg, Slaven | - |
dc.date.accessioned | 2015-10-20T09:01:23Z | - |
dc.date.available | 2015-10-20T09:01:23Z | - |
dc.date.issued | 2013-12-20 | - |
dc.identifier | doi: 10.1089/scd.2013.0266 | - |
dc.identifier | issn: 1547-3287 | - |
dc.identifier.citation | Stem Cells and Development 23(1): 1- 4 (2014) | - |
dc.identifier.uri | http://hdl.handle.net/10261/123569 | - |
dc.description.abstract | Halting the first clinical trial on the use of embryonic stem cell derivatives for spinal cord injury resulted in disappointment and created concerns about the future use of pluripotent stem cell-based therapy in the treatment of human diseases. This article presents reflections and concerns related to the halted embryonic stem cell-based clinical trial and discusses some important and controversial issues for achieving safe and successful cell therapy. This manuscript highlights two important points for successful translation of pluripotent stem cell-based therapy in clinics: (i) reproducible xeno-free growth and differentiation of pluripotent stem cells in good manufacturing practice conditions as the prerequisites to ensure a defined and controlled cell source and (ii) extensive studies in small and large animal models and comprehensive basic studies to determine any adverse or toxic effects of transplanted cells, especially teratoma formation, in addition to improving surgical procedure and cell delivery system | - |
dc.description.sponsorship | This work was supported by funds for research from ‘‘Miguel Servet’’ contract of Instituto de Salud Carlos III of Spanish Ministry of Science and Innovation (S.E.), fund for Health of Spain PI10-01683 (V.M.-M.), and Junta de Andalucia PI-0113-2010 (S.E.) | - |
dc.publisher | Mary Ann Liebert | - |
dc.relation.isversionof | Postprint | - |
dc.rights | closedAccess | - |
dc.title | Perspectives and future directions of human pluripotent stem cell-based Therapies: Lessons from geron's clinical trial for spinal cord injury | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1089/scd.2013.0266 | - |
dc.relation.publisherversion | http://dx.doi.org/10.1089/scd.2013.0266 | - |
dc.date.updated | 2015-10-20T09:01:23Z | - |
dc.description.version | Peer Reviewed | - |
dc.language.rfc3066 | eng | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | - |
dc.contributor.funder | Junta de Andalucía | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004837 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100011011 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (CABIMER) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
42
checked on 15-may-2024
WEB OF SCIENCETM
Citations
37
checked on 23-feb-2024
Page view(s)
290
checked on 16-may-2024
Download(s)
136
checked on 16-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.